Agios Pharmaceuticals, Inc. Forecast, price target & analysts
Agios Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Agios Pharmaceuticals, Inc. Classifications & Recommendation:
Agios Pharmaceuticals, Inc. Price Target
| Target Price | $54.06 |
| Price | $35.08 |
| Potential |
54.10%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Agios Pharmaceuticals, Inc. 2026 .
The average Agios Pharmaceuticals, Inc. target price is $54.06.
This is
54.10%
register free of charge
$68.25
94.56%
register free of charge
$39.39
12.29%
register free of charge
|
|
| A rating was issued by 15 analysts: 11 Analysts recommend Agios Pharmaceuticals, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Agios Pharmaceuticals, Inc. stock has an average upside potential 2026 of
54.10%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 36.50 | 43.41 |
| 36.09% | 18.93% | |
| EBITDA Margin | -1,150.90% | -1,123.43% |
| 19.80% | 2.39% | |
| Net Margin | 1,845.84% | -986.91% |
| 240.60% | 153.47% |
11 Analysts have issued a sales forecast Agios Pharmaceuticals, Inc. 2025 . The average Agios Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Agios Pharmaceuticals, Inc. EBITDA forecast 2025. The average Agios Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Agios Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Agios Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 11.64 | -7.38 |
| 283.89% | 163.40% | |
| P/E | negative | |
| EV/Sales | 25.32 |
11 Analysts have issued a Agios Pharmaceuticals, Inc. forecast for earnings per share. The average Agios Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Agios Pharmaceuticals, Inc....
Current Agios Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Scotiabank |
Locked
➜
Locked
|
Locked | Jul 28 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | May 02 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 18 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Dec 10 2024 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Dec 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Scotiabank:
Locked
➜
Locked
|
Jul 28 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jul 22 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
May 02 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 18 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Dec 10 2024 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Dec 09 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
